Cargando…

Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab

Peripheral exudative hemorrhagic chorioretinopathy (PEHCR) is a rare disorder that sometimes causes sudden subretinal and/or vitreous hemorrhage. Choroidal neovascularization is involved in the pathogenesis, but the etiology is unknown. Treatments with photocoagulation, cryopexy, and intravitreal be...

Descripción completa

Detalles Bibliográficos
Autores principales: Takayama, Kei, Enoki, Tosio, Kojima, Teruo, Ishikawa, Sho, Takeuchi, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392917/
https://www.ncbi.nlm.nih.gov/pubmed/22791965
http://dx.doi.org/10.2147/OPTH.S31640
_version_ 1782237668161093632
author Takayama, Kei
Enoki, Tosio
Kojima, Teruo
Ishikawa, Sho
Takeuchi, Masaru
author_facet Takayama, Kei
Enoki, Tosio
Kojima, Teruo
Ishikawa, Sho
Takeuchi, Masaru
author_sort Takayama, Kei
collection PubMed
description Peripheral exudative hemorrhagic chorioretinopathy (PEHCR) is a rare disorder that sometimes causes sudden subretinal and/or vitreous hemorrhage. Choroidal neovascularization is involved in the pathogenesis, but the etiology is unknown. Treatments with photocoagulation, cryopexy, and intravitreal bevacizumab injection have been reported. However, the therapeutic effect of intravitreal injection with ranibizumab for PEHCR is unclear. A 70-year-old woman visited our department because of sudden loss of superior visual field in her left eye. She had a history of surgical removal of hematoma due to subretinal hemorrhage associated with age-related macular degeneration 5 years ago. Peripheral subretinal hemorrhage was observed in the left eye, and fluorescein and indocyanine green angiography revealed choroidal neovascularization in the subretinal hemorrhagic region. PEHCR was diagnosed. Considering her past history, intravitreal ranibizumab injection was used for treatment. After three injections in the left eye, subretinal hemorrhage and choroidal neovascularization resolved completely. No recurrence was observed during 1 year of follow-up. This case demonstrates that intravitreal injection of ranibizumab is an effective treatment for PEHCR with subretinal hemorrhage.
format Online
Article
Text
id pubmed-3392917
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33929172012-07-12 Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab Takayama, Kei Enoki, Tosio Kojima, Teruo Ishikawa, Sho Takeuchi, Masaru Clin Ophthalmol Case Report Peripheral exudative hemorrhagic chorioretinopathy (PEHCR) is a rare disorder that sometimes causes sudden subretinal and/or vitreous hemorrhage. Choroidal neovascularization is involved in the pathogenesis, but the etiology is unknown. Treatments with photocoagulation, cryopexy, and intravitreal bevacizumab injection have been reported. However, the therapeutic effect of intravitreal injection with ranibizumab for PEHCR is unclear. A 70-year-old woman visited our department because of sudden loss of superior visual field in her left eye. She had a history of surgical removal of hematoma due to subretinal hemorrhage associated with age-related macular degeneration 5 years ago. Peripheral subretinal hemorrhage was observed in the left eye, and fluorescein and indocyanine green angiography revealed choroidal neovascularization in the subretinal hemorrhagic region. PEHCR was diagnosed. Considering her past history, intravitreal ranibizumab injection was used for treatment. After three injections in the left eye, subretinal hemorrhage and choroidal neovascularization resolved completely. No recurrence was observed during 1 year of follow-up. This case demonstrates that intravitreal injection of ranibizumab is an effective treatment for PEHCR with subretinal hemorrhage. Dove Medical Press 2012 2012-06-07 /pmc/articles/PMC3392917/ /pubmed/22791965 http://dx.doi.org/10.2147/OPTH.S31640 Text en © 2012 Takayama et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Report
Takayama, Kei
Enoki, Tosio
Kojima, Teruo
Ishikawa, Sho
Takeuchi, Masaru
Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
title Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
title_full Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
title_fullStr Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
title_full_unstemmed Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
title_short Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
title_sort treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392917/
https://www.ncbi.nlm.nih.gov/pubmed/22791965
http://dx.doi.org/10.2147/OPTH.S31640
work_keys_str_mv AT takayamakei treatmentofperipheralexudativehemorrhagicchorioretinopathybyintravitrealinjectionsofranibizumab
AT enokitosio treatmentofperipheralexudativehemorrhagicchorioretinopathybyintravitrealinjectionsofranibizumab
AT kojimateruo treatmentofperipheralexudativehemorrhagicchorioretinopathybyintravitrealinjectionsofranibizumab
AT ishikawasho treatmentofperipheralexudativehemorrhagicchorioretinopathybyintravitrealinjectionsofranibizumab
AT takeuchimasaru treatmentofperipheralexudativehemorrhagicchorioretinopathybyintravitrealinjectionsofranibizumab